Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) EBT (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed EBT for 9 consecutive years, with $17.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 41.72% year-over-year to $17.0 million, compared with a TTM value of $35.5 million through Dec 2025, up 51.26%, and an annual FY2024 reading of $24.1 million, changed N/A over the prior year.
  • EBT was $17.0 million for Q4 2025 at Puma Biotechnology, up from $9.1 million in the prior quarter.
  • Across five years, EBT topped out at $20.3 million in Q3 2024 and bottomed at -$44.6 million in Q3 2021.
  • Average EBT over 5 years is $2.2 million, with a median of $3.8 million recorded in 2021.
  • The sharpest move saw EBT soared 1877.81% in 2023, then tumbled 396.83% in 2024.
  • Year by year, EBT stood at $4.3 million in 2021, then soared by 67.38% to $7.3 million in 2022, then tumbled by 236.03% to -$9.9 million in 2023, then surged by 221.28% to $12.0 million in 2024, then soared by 41.72% to $17.0 million in 2025.
  • Business Quant data shows EBT for PBYI at $17.0 million in Q4 2025, $9.1 million in Q3 2025, and $6.2 million in Q2 2025.